2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
1997
Breast Cancer Risk Factors According to Combined Estrogen and Progesterone Receptor Status: A Case-Control Analysis
Yoo K, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R. Breast Cancer Risk Factors According to Combined Estrogen and Progesterone Receptor Status: A Case-Control Analysis. American Journal Of Epidemiology 1997, 146: 307-314. PMID: 9270409, DOI: 10.1093/oxfordjournals.aje.a009271.Peer-Reviewed Original ResearchConceptsProgesterone receptor statusHormone receptor statusReceptor statusEstrogen receptor statusRisk factorsBreast cancerAichi Cancer Center HospitalBreast cancer risk factorsDiagnosis/interviewReproductive risk factorsCancer Center HospitalCancer risk factorsGradient of riskBreast cancer casesCase-control analysisPolytomous logistic regressionCancer-free controlsCommon control groupStratification of casesJoint estrogenCenter HospitalMenstrual regularityCigarette smokingCombined EstrogenProgesterone receptor